UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash Flows From Operating Activities:
Net Loss	$ (7,350,000)	$ (7,984,000)	$ (7,855,000)	$ (8,679,000)	$ (22,227,000)	$ (26,826,000)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization					614,000	582,000
Stock-based Compensation					(276,000)	3,895,000
Warrant Modification Expense	0		0		837,000	0
Increase in Inventory Reserves					305,000	1,271,000
Amortization of Right of Use Asset					1,090,000	1,430,000
Amortization of Debt Financing Costs and Accretion of Debt Discount					200,000	0
Loss (Gain) on Disposal of Assets					7,000	(1,000)
Realized (Gain) on Sale of Investments Available-for-Sale					(8,000)	(24,000)
Foreign Currency Translation Adjustment					7,000	0
Changes in Assets and Liabilities:
Decrease in Accounts Receivable, net					74,000	1,857,000
Decrease in Insurance Receivable					0	371,000
(Increase) Decrease in Inventory					(953,000)	293,000
Decrease in Prepaid and Other Assets					161,000	931,000
Increase (Decrease) in Accounts Payable					1,172,000	(1,298,000)
Decrease in Settlement Payable					(104,000)	(147,000)
Decrease in Lease Liability					(1,056,000)	(1,369,000)
Increase (Decrease) in Other Liabilities					423,000	(1,229,000)
Decrease in Deferred License Revenue					(1,338,000)	(1,690,000)
Changes in Assets and Liabilities					(1,621,000)	(2,281,000)
Cash Used In Operating Activities					(21,072,000)	(21,954,000)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale					(23,531,000)	(34,202,000)
Sale of Investments Available-for-Sale					27,076,000	30,479,000
Purchase of Equipment					(970,000)	(449,000)
Purchase of Research and Development Licenses (Related Party)					0	(750,000)
Cash Provided By (Used In) Investing Activities					2,575,000	(4,922,000)
Cash Flows From Financing Activities:
Proceeds from Term Loan					22,500,000	0
Debt Issuance Costs					(1,343,000)	0
Payments on Short Term Note Payable					(763,000)	(763,000)
Proceeds from the Exercise of Employee Stock Options					0	148,000
Repurchase of Common Stock to Pay Employee Withholding Taxes					(18,000)	(180,000)
Cash Provided By Financing Activities					63,317,000	18,583,000
Increase (Decrease) in Cash and Cash Equivalents					44,820,000	(8,293,000)
Cash and Cash Equivalents at Beginning of Period		$ 11,794,000		$ 22,714,000	11,794,000	22,714,000	$ 22,714,000
Cash and Cash Equivalents at End of Period	$ 56,614,000		$ 14,421,000		56,614,000	14,421,000	11,794,000
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest					906,000	0
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale					(11,000)	0
Insurance Financing Note Payable					0	1,145,000
Fair Value of Warrants issued related to Debt Financing					501,000	0
Public offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering					43,148,000	18,777,000
Offering Costs from the Issuance of Common Stock / Public Offering					(2,469,000)	(1,488,000)
At-the-market offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering					2,325,478	2,296,000	5,383,079
Offering Costs from the Issuance of Common Stock / Public Offering					$ (63,000)	$ (207,000)	$ (309,479)